Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-interventional study of Depigoid Phleum in grass pollen–induced allergic rhinitis/rhinoconjunctivitis with or without asthma
2013-004920-12Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Dec 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of depigoid phleum in allergic rhinitis (AR), allergic conjunctivitis (AC), allergic rhinoconjunctivitis (ARC) and 1 more, sponsored by LETI Pharma. Primary endpoint: Symptom and Rescue Medication Score (SMS). Started Dec 2013; status: completed.
02
Drugs
depigoid phleum
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2013-004920-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004920-12.